Home
Diseases
Colorectal Cancer

Colorectal Cancer

Disease

Also known as: CC

Disease Profile

Colorectal cancer is cancer that begins in the colon or rectum. It is one of the most common gastrointestinal cancers and a major cause of cancer burden worldwide.

Category: Gastrointestinal malignancy
Prevalence: Estimated 1,416,499 people living with colorectal cancer in the U.S. (2022)

ICD Codes

Related News

Multiple Studies Link Accelerated Biological Aging to Rising Early-Onset Cancer in Younger Generations

Jun 29, 2026

Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.

New Research Advances Cancer Immunotherapy Through Clinical Data, Resistance Mechanisms, and Microbiome Insights

Jun 21, 2026

New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.

Cantargia Reports 2025 Financials, Secures Financing to Accelerate Nadunolimab Development

Jun 21, 2026

Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.

Allarity Therapeutics Presents Stenoparib Ovarian Cancer Trial at ESMO Congress

Jun 19, 2026

Allarity Therapeutics will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026 on its Phase 2 ovarian cancer trial of stenoparib. The company also dosed first patients in February 2026 in a VA-funded Phase 2 trial of stenoparib plus temozolomide for relapsed small cell lung cancer.

CStone Receives FDA Clearance to Advance CS2009 Trispecific Antibody to Phase II Trials

Jun 12, 2026

The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.

AI and mRNA Cancer Vaccine Shows 49% Reduction in Melanoma Relapse at ASCO 2026

Jun 11, 2026

Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.

Racial Disparities Persist Across Cancer Incidence and Clinical Trial Outcomes

Jun 02, 2026

Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.

NHS-Galleri Trial Misses Primary Endpoint but Shows 26% Reduction in Stage IV Cancer by Third Round

May 31, 2026

The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.

Tempus AI Launches Preview Tool for Early Cancer Insights Within 24 Hours

May 30, 2026

Tempus has launched "Preview," an AI-powered tool that provides early cancer insights within one day of sample receipt to inform treatment planning. The tool focuses on high-impact biomarkers including MSI-H, EGFR mutations, and FGFR fusions across several cancer types. The launch aligns with expert emphasis on the critical role of early biomarker testing in personalizing therapy for EGFR-mutated NSCLC.

Studies Highlight Variation in Colorectal Cancer Care and Support Needs

May 10, 2026

Research found variation in guideline-concordant colorectal cancer care across hospitals and systems, while a separate study highlighted the role of specialized cancer nurses in reducing distress and improving support.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07614048	Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS	TEMPORARILY_NOT_AVAILABLE
NCT07609680	MAP- Versus Cardiac Index-Guided Hemodynamic Management in Colorectal Surgery	NOT_YET_RECRUITING	NA
NCT07605702	The Canopy Cancer Collective Clinical Registry Protocol	NOT_YET_RECRUITING
NCT07604909	A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy	RECRUITING	PHASE2
NCT07599501	Nutritional Supplementation to Improve Colorectal Cancer Surgery	NOT_YET_RECRUITING	NA
NCT07597759	Phase IIT Trial of SNA009	COMPLETED	EARLY_PHASE1
NCT07595276	Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.	NOT_YET_RECRUITING	PHASE3
NCT07594067	TCR1188-ABC Cells in KRAS-mutated Cancers	NOT_YET_RECRUITING	PHASE1
NCT07592338	Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer	COMPLETED
NCT07590856	A Preliminary Efficacy of SNA028 in Patients With Advanced Colorectal Cancer Positive for GPA33	NOT_YET_RECRUITING	EARLY_PHASE1